ALA-1000 Receive notice of patent allowance from Innovation, Science and Economic Development Canada (ISED) on May 10, 2021, Application No.3,033,046.
ALA-1000 Receive notice of patent allowance from the IP New Zealand on April 30, 2021. Patent No. 750367
ALA-1000 Receive notice of allowance for patent registration from Korean Intellectual Property Office on April 16, 2021 (Application No. 10-2019-7009185).
ALA-1000 Receive Decision of Grant from Federal Service for Intellectual Property (ROSPATENT) on April 12, 2021 (Application No. 2019102895).
- Listed on Taipei Exchange Market in Taiwan on 23 September ，Traded on October 5
- ALA-1000 Receive notice of patent allowance from the IP Australia.
- ALA-3000 completes Pre-IND Meeting with US FDA
- ALA-1000 Receive notice of patent allowance from the Mexican Institute of Industrial Property (IMPI)
- Approved to be a public offering company on June 3. Code : ( 6785 )
- Receive notice of patent allowance from USPTO ( ALA-1000)
- ALA-1000 was approved by Ministry of Economic Affairs : A+ Industrial Innovation R&D Program(fast track)
Approved by the Ministry of Economic Affairs as a Biotech Pharmaceutical company
ALA-1000 received US FDA IND approval.
Approved to locate in Central Science Park
- ALA-1000 was approved by Ministry of Economic Affairs ：A+ Industrial Innovation R&D Program－Industrial Technology Foresight Research Program
- Alar Pharmaceuticals Inc was founded